DURHAM – Bioventus, a orthobiologic company focused on osteoarthritis, surgical and non-surgical bone healing, is getting a new chief executive officer.
Current CEO Tony Bihl is “electing to retire,” the company says.
Replacing him will be industry veteran Ken Reali. He will also join the Bioventus board.
Renali is no stranger to the company.
Ken Reali
Reali “worked within the Clinical Therapies business of Smith & Nephew over a decade ago which was later spun out to become Bioventus,” the company noted..
“I am honored to have the opportunity to lead Bioventus,” said Reali in the announcement. “The company’s broad product portfolio, global presence and solid growth have it well positioned to serve the needs of patients and physicians. Even more successes lie ahead and I’m excited to work with the talented Bioventus team to drive strong value for all stakeholders.”
Reali is former CEO of Clinical Innovations, a medical device company, which recently was sold. He served as CEO from June 2015 to Feb. 12 of this year.
